ReviewDrugs & aging2012
Melatonin prolonged release: in the treatment of insomnia in patients aged ≥55 years.
Review in Drugs & aging, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03833570 (The Effectiveness of Melatonin in Prevention of Radiation-induced Oral Mucositis), which is not on this map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effectiveness of Melatonin in Prevention of Radiation-induced Oral Mucositis
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 62 citations in OpenAlex.
- Significant potential of melatonin therapy in Parkinson's disease - a meta-analysis of randomized controlled trials.Frontiers in neurology · 2023Pooled it
- Effect of melatonin supplementation on sleep quality: a systematic review and meta-analysis of randomized controlled trials.Journal of neurology · 2022Pooled it
- Melatonin 4 mg as prophylactic therapy for primary headaches: a pilot study.Functional neurologyTrial
- Effect of graduated drug therapy for moderate-to-severe chronic insomnia on the severity of disease: an observational study in Germany.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2025Observational
- Essential Oils and Melatonin as Functional Ingredients in Dogs.Animals : an open access journal from MDPI · 2022Review
- Drug safety profiles in geriatric patients with Parkinson's disease using the FORTA (Fit fOR The Aged) classification: results from a mono-centric retrospective analysis.Journal of neural transmission (Vienna, Austria : 1996) · 2021Article
- Development of a Phytomelatonin-Rich Extract from Cultured Plants with Excellent Biochemical and Functional Properties as an Alternative to Synthetic Melatonin.Antioxidants (Basel, Switzerland) · 2020Article
- Prolonged-release melatonin in patients with idiopathic REM sleep behavior disorder.Annals of clinical and translational neurology · 2019Article
- Screening of melatonin, α-tocopherol, folic acid, acetyl-L-carnitine and resveratrol for anti-dengue 2 virus activity.BMC research notes · 2018Article
- Popular Herbal and Natural Remedies Used in Psychiatry.Focus (American Psychiatric Publishing) · 2018Article
- Over-the-counter medications containing diphenhydramine and doxylamine used by older adults to improve sleep.International journal of clinical pharmacy · 2017Article
- Association of Urinary 6-Sulfatoxymelatonin (aMT6s) Levels and Objective and Subjective Sleep Measures in Older Men: The MrOS Sleep Study.The journals of gerontology. Series A, Biological sciences and medical sciences · 2015Article
- Melatonin attenuates inflammation of acute pulpitis subjected to dental pulp injury.American journal of translational research · 2015Article
- Wake-active neurons across aging and neurodegeneration: a potential role for sleep disturbances in promoting disease.SpringerPlus · 2015Article
- [Sleep and sleep disorders in the elderly. Part 2: therapy].Zeitschrift fur Gerontologie und Geriatrie · 2014Review
- Sleep disturbance in older ICU patients.Clinical interventions in aging · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melatonin prolonged release (PR) 2 mg is approved for the treatment of primary insomnia characterized by poor sleep quality in patients aged ≥55 years in the EU and elsewhere. Patients may receive treatment with melatonin PR for up to 13 weeks. Production of endogenous nocturnal melatonin, which helps regulate circadian rhythm, may be decreased in older adults. Administration of melatonin PR 2 mg 1-2 h before bedtime mimics the natural secretion pattern of melatonin, thereby leading to improvements in the circadian regulation of the sleep-wake cycle. In older adults, melatonin PR 2 mg had no effect on psychomotor functions, memory recall or driving skills during the night or the next morning relative to placebo, and was associated with significantly less impairment on many of these tasks relative to zolpidem 10 mg alone or in combination with melatonin PR 2 mg. In 3-week and 6-month, randomized, double-blind clinical trials in patients with primary insomnia aged ≥55 years, melatonin PR 2 mg 1-2 h before bedtime was associated with significant improvements relative to placebo in many sleep and daytime parameters, including sleep quality and latency, morning alertness and health-related quality of life. Melatonin PR 2 mg was very well tolerated in clinical trials in older patients, with a tolerability profile that was similar to that of placebo. Short- or longer-term treatment with melatonin PR 2 mg was not associated with dependence, tolerance, rebound insomnia or withdrawal symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.